ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases
2024年8月15日 - 6:00PM
ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.
-based biotechnology company focused on developing cell and
gene-based treatments for aging, and age-related diseases, today
announced the grant and issuance of U.S. Patent No. 12,036,268
(“the 268 patent”) covering the secreted RNA splice variant of the
human Klotho gene, referred to as “s-KL”, for the treatment of
cognitive and neurodegenerative diseases.
The human Klotho gene, sometimes referred to as
the “anti-aging” gene, also controls many normal brain and
neurologic functions. The Klotho gene-therapy patent in the U.S. is
instrumental new intellectual property (“IP”) protecting its
development and commercialization in the U.S. ANEW previously
announced that patents have already been granted and issued in
Europe, China, and other Asian markets.
ANEW’s IP portfolio has been licensed on an
exclusive worldwide basis from the Universitat Autònoma de
Barcelona (UAB) and Institució Catalana De Recerca Estudis Avançats
(ICREA) in Barcelona, Spain, and provides ANEW with rights to
develop and commercialize novel genetic approaches for the
treatment of neurodegenerative diseases, including Alzheimer’s,
amyotrophic lateral sclerosis (ALS or “Lou Gehrig’s disease”),
Parkinson’s disease, and other age-related disorders. Replacing or
augmenting the production of the gene product, s-KL, may also be
used to support longevity.
“This is a major win for ANEW and our
shareholders,” commented Dr. Joseph Sinkule, the Founder, Chairman
and CEO of ANEW. “It provides us with the protection we need to
successfully move forward with the development of our innovative
protein, cell and gene therapies using our patented sequence and
use of s-KL secreted Klotho RNA splice variant sequence and
delivery systems to treat these devastating neurodegenerative
diseases. With the issuance of this important patent in the USA,
ANEW has secured an enviable global IP position with patents
already issued in Europe, China, Hong Kong, and Japan.”
About ANEW MEDICAL, INC.ANEW
MEDICAL, INC. (NASDAQ: WENA) is a biopharmaceutical company
specializing in the development of patented, novel
disease-modifying technologies targeting the brain and central
nervous system (CNS) that are seen as key developments in treating
neurodegenerative and age-related disorders. The Company obtained
exclusive worldwide rights to platform technologies and knowhow to
develop cutting edge protein, gene and cell therapies to treat
age-related pathologies such as Alzheimer’s and Parkinson’s
Disease, ALS, multiple sclerosis and rare neurodegenerative
diseases. The company is managed by a team of individuals and
advisors who are highly experienced in biopharmaceutical product
development and commercialization.
For more information,
contact:Eric BoydInvestor RelationsEmail:
IR@anewmeds.com
Forward-Looking Statements:This
press release contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, such as the Company’s inability to implement its business
plans, identify and realize additional opportunities, or meet or
exceed its financial projections and changes in the regulatory or
competitive environment in which the Company operates. You should
carefully consider the foregoing factors and the other risks and
uncertainties described in the documents filed or to be filed by
the Company with the U.S. Securities and Exchange Commission (the
“SEC”) from time to time, which could cause actual events and
results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided herein
is as of the date of this press release, and the Company undertakes
no obligation to update any forward-looking statement, except as
required under applicable law.
ANEW MEDICAL (NASDAQ:WENA)
過去 株価チャート
から 7 2024 まで 8 2024
ANEW MEDICAL (NASDAQ:WENA)
過去 株価チャート
から 8 2023 まで 8 2024